myasthenia gravis
Information
- Disease name
- myasthenia gravis
- Disease ID
- DOID:437
- Description
- "An autoimmune disease of the nervous system that has_material_basis_in antibodies to acetylcholine receptors at the neuromuscular junction, has_symptom ptosis, has_symptom diplopia, has_symptom dysphagia, has_symptom dysarthria, has_symptom muscle weakness and has_symptom shortness of breath." [url:https\://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Myasthenia-Gravis-Fact-Sheet]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| MEFV | 16 | 3,242,027 | 3,256,633 | 8 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00716066 | Active, not recruiting | Phase 2 | Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases | June 2008 | January 31, 2030 |
| NCT05455840 | Active, not recruiting | N/A | A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Anterior Mediastinal Disease | August 3, 2022 | April 11, 2024 |
| NCT04678115 | Active, not recruiting | N/A | Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis | June 1, 2021 | December 31, 2024 |
| NCT04524273 | Active, not recruiting | Phase 3 | Myasthenia Gravis Inebilizumab Trial | August 30, 2020 | November 29, 2027 |
| NCT05150210 | Active, not recruiting | N/A | SP Thoracic IDE Study | July 20, 2022 | July 2028 |
| NCT00774462 | Completed | Phase 2 | Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis | January 2008 | December 2011 |
| NCT00814138 | Completed | Phase 2 | Efficacy of Methotrexate in Myasthenia Gravis | April 2009 | January 2014 |
| NCT00987116 | Completed | Phase 4 | Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis | June 2009 | September 2017 |
| NCT04346888 | Completed | Phase 2 | A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients | July 23, 2020 | August 24, 2021 |
| NCT00309088 | Completed | Phase 3 | FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients | April 2006 | June 2008 |
| NCT04695379 | Completed | Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection | April 27, 2020 | June 18, 2020 | |
| NCT00309101 | Completed | Phase 3 | An Open Study for Steroid Resistant, Non-Thymectomized MG Patients | February 2006 | February 2009 |
| NCT04590716 | Completed | Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares | October 2, 2020 | July 26, 2021 | |
| NCT03905473 | Completed | Physical Activity and Fatigue in Myasthenia Gravis | June 1, 2019 | October 10, 2020 | |
| NCT05230082 | Completed | N/A | Acupuncture in Myasthenia Gravis (AcuMG) | May 25, 2022 | April 30, 2024 |
| NCT03941184 | Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity | January 1, 1995 | November 10, 2020 | |
| NCT03979521 | Completed | Burden of Disease in Myasthenia Gravis | May 1, 2019 | July 31, 2019 | |
| NCT00306033 | Completed | Phase 3 | Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis | March 2004 | May 2005 |
| NCT04159805 | Completed | Phase 2 | A Study of TAK-079 in People With Generalized Myasthenia Gravis | January 14, 2020 | July 12, 2022 |
| NCT04176211 | Completed | The Impact of Myasthenia Gravis in the Real World | December 12, 2019 | May 31, 2024 | |
| NCT05045248 | Completed | Phase 2 | Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis | June 1, 2020 | April 15, 2021 |
| NCT05039190 | Completed | Phase 3 | Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients | September 25, 2021 | January 14, 2023 |
| NCT06256172 | Completed | N/A | Medlink for Diagnosing of Diabetes Mellitus, COPD, CHF, Myasthenia Gravis and Hypertension | June 16, 2023 | December 16, 2023 |
| NCT01102192 | Completed | The Role of the Thymus in Myasthenia Gravis | August 2007 | December 2012 | |
| NCT01325571 | Completed | Phase 3 | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis | March 2011 | May 2014 |
| NCT06101407 | Completed | Univent Tube for Thoracoscopic Thymectomy in Myasthenic Patients | January 15, 2016 | December 25, 2019 | |
| NCT01727193 | Completed | Phase 3 | The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy | September 2012 | November 18, 2021 |
| NCT00285350 | Completed | Phase 3 | Mycophenolate Mofetil in Myasthenia Gravis | September 2002 | March 2007 |
| NCT05945784 | Completed | Exploring Accessible Beauty for Individuals With Upper Extremity Deficits | July 21, 2023 | September 29, 2023 | |
| NCT01927692 | Completed | Therapeutic Plasma Exchange in MG | July 2013 | October 2014 | |
| NCT02066519 | Completed | N/A | Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis | October 2014 | April 6, 2018 |
| NCT02100969 | Completed | Phase 2 | Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis | May 2015 | January 2018 |
| NCT05917184 | Completed | The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis | August 30, 2021 | January 20, 2023 | |
| NCT02110706 | Completed | Phase 2 | BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis | May 2014 | May 2018 |
| NCT02118805 | Completed | Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders | October 2013 | December 31, 2021 | |
| NCT02470364 | Completed | Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F | June 2014 | ||
| NCT02473965 | Completed | Phase 2 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | June 2015 | February 2019 |
| NCT02609022 | Completed | Phase 1/Phase 2 | Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis | March 2016 | September 30, 2018 |
| NCT02761707 | Completed | Biomarkers in Neural Disorders | June 2016 | July 16, 2019 | |
| NCT02774239 | Completed | Phase 3 | A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) | October 2014 | October 21, 2022 |
| NCT02902536 | Completed | Tissue Repository for Studies of Myasthenia Gravis | August 2015 | August 31, 2019 | |
| NCT02965573 | Completed | Phase 2 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness | December 30, 2016 | October 20, 2017 |
| NCT03052751 | Completed | Phase 2 | Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis | May 15, 2017 | August 6, 2018 |
| NCT05694234 | Completed | Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study | September 1, 2021 | December 30, 2021 | |
| NCT03205306 | Completed | Myasthenia Gravis and Psyche | May 8, 2017 | December 14, 2017 | |
| NCT05408702 | Completed | Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes | November 12, 2021 | May 15, 2022 | |
| NCT05324176 | Completed | N/A | Diaphragm Thickness by Ultrasonography in Neurological Disorders | April 13, 2022 | May 13, 2022 |
| NCT03743740 | Completed | N/A | The Effect of Spinal Stabilization Exercises in Patients With Myasthenia Gravis | December 3, 2018 | April 8, 2019 |
| NCT03759366 | Completed | Phase 3 | A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) | December 21, 2018 | November 6, 2023 |
| NCT00294658 | Completed | Phase 3 | Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy | June 2006 | December 2015 |
| NCT03818204 | Completed | N/A | Clinical Trial to Improve the Magnetic Levator Prosthesis | February 7, 2019 | December 1, 2023 |
| NCT03826056 | Completed | N/A | Neurology Inpatient Clinical Education Trial | February 1, 2019 | December 7, 2021 |
| NCT03863080 | Completed | Phase 2 | A Study of RVT-1401 in Myasthenia Gravis (MG) Patients | May 21, 2019 | December 21, 2020 |
| NCT03905161 | Completed | Rhythmic Auditory Stimulation and Walking Speed in the 6-minute Walk Test | February 10, 2019 | January 10, 2020 | |
| NCT00704626 | Enrolling by invitation | Serum Auto-Antibodies in Neurological Diseases | January 2002 | March 2031 | |
| NCT05888558 | Enrolling by invitation | Screening of Serum Exosomal miRNA as a Biomarker for Ocular Muscle Myasthenia Gravis | July 4, 2023 | May 31, 2024 | |
| NCT06371040 | Not yet recruiting | Phase 1 | Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis | May 1, 2024 | December 1, 2026 |
| NCT06221501 | Not yet recruiting | Phase 2 | Perioperative Efgartigimod for Thymoma and Myasthenia Gravis | February 1, 2024 | June 30, 2027 |
| NCT06193889 | Not yet recruiting | Phase 2 | A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis | March 2024 | May 2027 |
| NCT06064461 | Not yet recruiting | Vitaccess Real MG Registry | March 2024 | March 2034 | |
| NCT06298565 | Not yet recruiting | A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | June 2024 | June 2034 | |
| NCT06414954 | Not yet recruiting | Phase 2 | Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | May 2024 | November 2025 |
| NCT05301153 | Not yet recruiting | Interleukin and Autoantibodies in Myasthenia Gravis. | July 1, 2022 | December 1, 2024 | |
| NCT02317224 | Recruiting | Phase 2 | The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor | August 2014 | December 2024 |
| NCT01793168 | Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford | July 2010 | December 2100 | |
| NCT03792659 | Recruiting | The EXPLORE MG Registry for Myasthenia Gravis | March 30, 2016 | October 30, 2026 | |
| NCT04101578 | Recruiting | Clinical Prognosis and Progression of Myasthenia Gravis Patients | February 8, 2017 | December 31, 2024 | |
| NCT04535843 | Recruiting | Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China | February 1, 2024 | May 1, 2028 | |
| NCT04561557 | Recruiting | Early Phase 1 | Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | September 22, 2020 | May 31, 2027 |
| NCT04728425 | Recruiting | Phase 2 | Subcutaneous Immunoglobulin for Myasthenia Gravis | August 28, 2020 | December 30, 2023 |
| NCT04768465 | Recruiting | Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis | January 1, 2021 | October 31, 2024 | |
| NCT04837625 | Recruiting | Study of Myasthenic Crisis in China | October 1, 2020 | September 30, 2026 | |
| NCT04951622 | Recruiting | Phase 3 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | July 15, 2021 | April 17, 2026 |
| NCT05214612 | Recruiting | Predictors and Prognostic Factors of Myasthenia Gravis Outcome | January 1, 2022 | August 31, 2024 | |
| NCT05265273 | Recruiting | Phase 2/Phase 3 | A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | July 20, 2022 | December 30, 2025 |
| NCT05332210 | Recruiting | Phase 3 | Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis | June 30, 2022 | December 30, 2023 |
| NCT05337891 | Recruiting | Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia Gravis | June 3, 2022 | September 1, 2024 | |
| NCT05564936 | Recruiting | N/A | The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis | January 24, 2024 | September 15, 2025 |
| NCT05566964 | Recruiting | Descriptive Analysis of Real-world Data Collected With ME&MGopen | February 27, 2023 | August 1, 2025 | |
| NCT05635266 | Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | October 26, 2021 | October 2025 | |
| NCT05828225 | Recruiting | Phase 1 | Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis | April 30, 2023 | April 20, 2026 |
| NCT05890833 | Recruiting | The Risk of Falls Index for Patients With Neuromuscular Disorders | September 1, 2023 | September 1, 2025 | |
| NCT05919407 | Recruiting | Phase 3 | Pyridostigmine and Amifampridine for Myasthenia Gravis | March 22, 2023 | September 22, 2024 |
| NCT05992025 | Recruiting | N/A | Digital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis | July 10, 2023 | July 2025 |
| NCT06002945 | Recruiting | Exploring Outcomes and Characteristics of Myasthenia Gravis 2 | January 12, 2021 | December 2026 | |
| NCT06006832 | Recruiting | A Prospective Cohort Study of Myasthenia Gravis in China | August 20, 2023 | September 30, 2026 | |
| NCT06106672 | Recruiting | Phase 1/Phase 2 | Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | May 30, 2024 | August 2026 |
| NCT06158815 | Recruiting | N/A | Investigation of the Effects of Proprioceptive Neuromuscular Facilitation Exercises in Patients With Myasthenia Gravis | December 28, 2022 | December 2024 |
| NCT06241521 | Recruiting | Myasthenia Gravis Registry in China | February 1, 2024 | January 30, 2035 | |
| NCT06259071 | Recruiting | MuSK Myasthenia 1000 Study | August 23, 2023 | December 31, 2025 | |
| NCT06277830 | Recruiting | Physical Activity Monitoring in Myasthenia Gravis | February 14, 2024 | June 2024 | |
| NCT06299748 | Recruiting | A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding. | May 2, 2024 | December 2033 | |
| NCT06381284 | Recruiting | Feasibility of Engaging and Capturing Undiagnosed Myasthenia Gravis Participants Through a Social Media Campaign Paired With a Self-moderated Assessment | March 28, 2024 | May 27, 2025 | |
| NCT06441825 | Recruiting | Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis | May 2, 2024 | October 31, 2025 | |
| NCT06443333 | Recruiting | National, Multicentric Registry Study on Neuroimmunological Diseases in China | December 1, 2020 | December 30, 2024 | |
| NCT03059888 | Terminated | Early Phase 1 | Trial of Orencia in Patients With Myasthenia Gravis | April 12, 2017 | July 15, 2019 |
| NCT00424489 | Terminated | Phase 1 | Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis | February 2002 | June 2016 |
| NCT00004682 | Terminated | N/A | Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis | March 1995 | March 1999 |
| NCT00727194 | Terminated | Phase 2 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis | October 2008 | July 2011 |
| NCT02102594 | Terminated | Phase 2 | Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) | October 2014 | August 30, 2019 |
| NCT05132569 | Terminated | Phase 3 | Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis | December 3, 2021 | February 21, 2023 |
| NCT01268280 | Terminated | Phase 2 | Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis | December 2010 | October 2012 |
| NCT05218096 | Terminated | Phase 2 | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | April 27, 2022 | April 3, 2024 |
| NCT01828294 | Terminated | Phase 1 | Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis | October 2011 | December 2017 |
| NCT04224506 | Unknown status | A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis | March 2, 2020 | July 2023 | |
| NCT01047761 | Unknown status | Phase 1 | Exercise for Stable Myasthenia Gravis | January 2010 | December 2020 |
| NCT04158661 | Unknown status | Influence of Minimally Invasive Thymectomy on the Subsequent Clinical Course of Myasthenia Gravis | April 20, 2020 | June 30, 2022 | |
| NCT01555580 | Unknown status | Early Phase 1 | A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis | April 2012 | December 2013 |
| NCT01469858 | Unknown status | N/A | Perception and Multisensory Integration in Neurological Patients Using fMRI | November 2011 | November 2015 |
| NCT03914638 | Unknown status | Phase 2/Phase 3 | Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis | April 1, 2019 | October 31, 2021 |
| NCT04674605 | Unknown status | A Prospective Cohort Study Of Myasthenia Gravis | December 31, 2020 | October 30, 2022 | |
| NCT04226170 | Unknown status | Phase 2 | Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis | April 8, 2021 | April 30, 2023 |
| NCT05095103 | Unknown status | Immune Profiles in Myasthenia Gravis | October 2021 | April 2024 | |
| NCT03613272 | Unknown status | N/A | The Curative Effect of Extended Thymectomy Performed Through Subxiphoid-right VATS Approach With Elevation of Sternum | July 1, 2018 | December 1, 2023 |
| NCT01105923 | Unknown status | N/A | Study of an Intervention to Improve Problem List Accuracy and Use | May 2010 | November 2017 |
| NCT00997412 | Unknown status | N/A | Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis | May 2009 | May 2011 |
| NCT03597373 | Unknown status | Variables Predicting Reintubation After Thymectomy in Patients With Myasthenia Gravis | January 1, 2017 | January 1, 2019 | |
| NCT03510546 | Unknown status | Phase 4 | Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis | April 9, 2018 | August 31, 2021 |
| NCT04965987 | Unknown status | Phase 1 | Oxaloacetate in Myasthenia Gravis | October 2021 | April 2023 |
| NCT03900585 | Withdrawn | N/A | Can Interval Walking Influence on Fatigue in the Danish Cohort of Myasthenia Gravis Patients | August 2019 | January 1, 2021 |
| NCT04541875 | Withdrawn | Medication Adherence and Non-adherence in Adults With Rare Disease | January 2021 | September 2022 |
- Disase is a (Disease Ontology)
- DOID:438
- Cross Reference ID (Disease Ontology)
- GARD:7122
- Cross Reference ID (Disease Ontology)
- ICD10CM:G70.0
- Cross Reference ID (Disease Ontology)
- ICD10CM:G70.00
- Cross Reference ID (Disease Ontology)
- ICD9CM:358.0
- Cross Reference ID (Disease Ontology)
- ICD9CM:358.00
- Cross Reference ID (Disease Ontology)
- MESH:D009157
- Cross Reference ID (Disease Ontology)
- MIM:254200
- Cross Reference ID (Disease Ontology)
- NCI:C60989
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:155092009
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0026896
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1260409
- OrphaNumber from OrphaNet (Orphanet)
- 589
- ICD10 preferred id (Insert disease from ICD10)
- D0005508
- ICD10 class code (Insert disease from ICD10)
- G70.0
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009157